A comment on ‘Glucagon‐like peptide‐1 receptor agonists and risk of thyroid cancer: A systematic review and meta‐analysis of randomized controlled trials’
Diabetes, Obesity and Metabolism · 2024
DOI: 10.1111/dom.15588 ↗Kurz gefasst
Leserbrief in der Zeitschrift Diabetes, Obesity and Metabolism, 2024. Verfasst von Ronald M Goldenberg. Beteiligte Einrichtung: LMC Diabetes & Endocrinology, Vaughan, Ontario, Canada. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Thyroid Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 6 Literaturangaben.
Abstract (Originalsprache)
The peer review history for this article is available at https://www.webofscience.com/api/gateway/wos/peer-review/10.1111/dom.15588. Data sharing is not applicable to this article as no new data were created.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- LMC Diabetes & Endocrinology, Vaughan, Ontario, Canada.
ORCID-Profile: Ronald M Goldenberg
Zitieren
APA
Goldenberg, R. M. (2024). A comment on ‘Glucagon‐like peptide‐1 receptor agonists and risk of thyroid cancer: A systematic review and meta‐analysis of randomized controlled trials’. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15588
Vancouver
Goldenberg RM. A comment on ‘Glucagon‐like peptide‐1 receptor agonists and risk of thyroid cancer: A systematic review and meta‐analysis of randomized controlled trials’. Diabetes, Obesity and Metabolism. 2024. doi:10.1111/dom.15588
BibTeX
@article{Goldenberg2024,
author = {Goldenberg, Ronald M},
title = {A comment on ‘Glucagon‐like peptide‐1 receptor agonists and risk of thyroid cancer: A systematic review and meta‐analysis of randomized controlled trials’},
journal = {Diabetes, Obesity and Metabolism},
year = {2024},
doi = {10.1111/dom.15588}
}
EUVIMED